Advertisement

Topics

Roche Gains EC Approval for Tecentriq in Metastatic Lung & Bladder Cancer

14:00 EDT 26 Sep 2017 | Drug Discovery Development

News
Related Biotechnology, Pharmaceutical and Healthcare News
The Phase III OAKstudy showed that TECENTRIQ helped people in the overall study population live a median of 13.8 months.
Contributed Author: 
Roche
Topics: 
Clinical Trials

Original Article: Roche Gains EC Approval for Tecentriq in Metastatic Lung & Bladder Cancer

NEXT ARTICLE

More From BioPortfolio on "Roche Gains EC Approval for Tecentriq in Metastatic Lung & Bladder Cancer"

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.